The AIM Vaccine Group has always been committed to the mission of "producing ethical vaccines to benefit the health of all people". It strictly controls vaccine quality and has four production bases and three research institutes. Currently, the products on the market mainly include recombinant hepatitis B vaccine (hansenula polymorpha), freeze-dried human rabies vaccine (Vero cells), inactivated hepatitis A vaccine (human diploid cells), mumps attenuated live vaccine, bivalent hemorrhagic fever with renal syndrome inactivated vaccine (Vero cells), and ACYW135 group meningococcal polysaccharide vaccine (MPSV4). AIM Persistence Biopharmaceutical Company is a wholly-owned subsidiary of AIM Vaccine Corporation (AIM Vaccine Group), founded in December 2002. It is a biopharmaceutical enterprise specializing in research, production and sales of human vaccines. The company's registered capital is 102,730,612 yuan, with a factory area of 90 acres, a building area of 83,000 square meters, a purification workshop of 16,000 square meters, and currently has 350 employees. Since its establishment, the company has had extensive project and technical cooperation relationships with domestic and foreign research institutions and universities, and has received strong support from the Ningbo Municipal Government. It has been determined as a key-supported and priority-developed high-tech enterprise in Ningbo. The company aims for survival through quality, with the goals of leapfrog development and caring for society. It bases its cooperation on mutual benefit and common development, continuously optimizes the industrial structure and human resource allocation, and is willing to establish extensive partnerships with all sectors of society to create brilliance together.